KR102275758B1 - 암 치료를 위한 제약학적 조합물 - Google Patents

암 치료를 위한 제약학적 조합물 Download PDF

Info

Publication number
KR102275758B1
KR102275758B1 KR1020187030575A KR20187030575A KR102275758B1 KR 102275758 B1 KR102275758 B1 KR 102275758B1 KR 1020187030575 A KR1020187030575 A KR 1020187030575A KR 20187030575 A KR20187030575 A KR 20187030575A KR 102275758 B1 KR102275758 B1 KR 102275758B1
Authority
KR
South Korea
Prior art keywords
delete delete
cancer
inhibitor
lymphoma
bcl
Prior art date
Application number
KR1020187030575A
Other languages
English (en)
Korean (ko)
Other versions
KR20190039878A (ko
Inventor
리처드 클링호퍼
조요티 데이
Original Assignee
프레시지 바이오싸이언시스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프레시지 바이오싸이언시스, 인크. filed Critical 프레시지 바이오싸이언시스, 인크.
Priority to KR1020217021031A priority Critical patent/KR102494039B1/ko
Publication of KR20190039878A publication Critical patent/KR20190039878A/ko
Application granted granted Critical
Publication of KR102275758B1 publication Critical patent/KR102275758B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187030575A 2016-03-28 2017-03-28 암 치료를 위한 제약학적 조합물 KR102275758B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217021031A KR102494039B1 (ko) 2016-03-28 2017-03-28 암 치료를 위한 제약학적 조합물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662314356P 2016-03-28 2016-03-28
US62/314,356 2016-03-28
PCT/US2017/024618 WO2017172826A1 (en) 2016-03-28 2017-03-28 Pharmaceutical combinations for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217021031A Division KR102494039B1 (ko) 2016-03-28 2017-03-28 암 치료를 위한 제약학적 조합물

Publications (2)

Publication Number Publication Date
KR20190039878A KR20190039878A (ko) 2019-04-16
KR102275758B1 true KR102275758B1 (ko) 2021-07-12

Family

ID=59966407

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020237002852A KR102545392B1 (ko) 2016-03-28 2017-03-28 암 치료를 위한 제약학적 조합물
KR1020237037917A KR20230156443A (ko) 2016-03-28 2017-03-28 암 치료를 위한 제약학적 조합물
KR1020237019958A KR102599512B1 (ko) 2016-03-28 2017-03-28 암 치료를 위한 제약학적 조합물
KR1020187030575A KR102275758B1 (ko) 2016-03-28 2017-03-28 암 치료를 위한 제약학적 조합물
KR1020217021031A KR102494039B1 (ko) 2016-03-28 2017-03-28 암 치료를 위한 제약학적 조합물

Family Applications Before (3)

Application Number Title Priority Date Filing Date
KR1020237002852A KR102545392B1 (ko) 2016-03-28 2017-03-28 암 치료를 위한 제약학적 조합물
KR1020237037917A KR20230156443A (ko) 2016-03-28 2017-03-28 암 치료를 위한 제약학적 조합물
KR1020237019958A KR102599512B1 (ko) 2016-03-28 2017-03-28 암 치료를 위한 제약학적 조합물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217021031A KR102494039B1 (ko) 2016-03-28 2017-03-28 암 치료를 위한 제약학적 조합물

Country Status (13)

Country Link
US (3) US11135198B2 (zh)
EP (1) EP3436002A4 (zh)
JP (3) JP7114478B2 (zh)
KR (5) KR102545392B1 (zh)
CN (1) CN109689047A (zh)
AU (4) AU2017241914B2 (zh)
CA (2) CA3018932C (zh)
IL (3) IL295472B2 (zh)
MX (3) MX2018011666A (zh)
NZ (1) NZ747404A (zh)
RU (2) RU2726367C2 (zh)
WO (1) WO2017172826A1 (zh)
ZA (1) ZA201806819B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2624981T3 (es) 2011-07-01 2017-07-18 Dana-Farber Cancer Institute, Inc. Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario
JP6879740B2 (ja) 2013-12-13 2021-06-02 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
KR102545392B1 (ko) * 2016-03-28 2023-06-20 프레시지 바이오싸이언시스, 인크. 암 치료를 위한 제약학적 조합물
KR20200083532A (ko) * 2017-10-31 2020-07-08 에자이 알앤드디 매니지먼트 가부시키가이샤 적어도 1종의 스플라이세오솜 조정제, 및 bcl2 억제제, bcl2/bclxl 억제제 및 bclxl 억제제로부터 선택된 적어도 1종의 억제제를 포함하는 조합물 및 사용 방법
CN108261414B (zh) * 2018-01-11 2019-09-06 广西师范大学 一种治疗肺癌的药物组合物
CN108186642B (zh) * 2018-01-11 2019-11-08 广西师范大学 一种协同起作用治疗肺癌的药物组合物
AU2019322858A1 (en) * 2018-08-14 2021-04-01 Mei Pharma, Inc. Combination therapy
WO2020092615A1 (en) * 2018-11-01 2020-05-07 Oregon Health & Science University Treatments for venetoclax-resistant and venetoclax-sensitive acute myeloid leukemia
EP4041239A1 (en) * 2019-10-08 2022-08-17 Dana-Farber Cancer Institute, Inc. A pyrazolopyrimidine derivative as a hck inhibitor for use in therapy, in particular myd88 mutated diseases
WO2021226263A1 (en) * 2020-05-07 2021-11-11 Recurium Ip Holdings, Llc Combinations
CA3198938A1 (en) * 2020-11-19 2022-05-27 Sandra E. Wiley Treatment of kras mutant cancers
CN113018357A (zh) * 2021-02-08 2021-06-25 湖南农业大学 茶多酚和帕博西尼联合在制备治疗乳腺癌的制剂中的用途
EP4319744A1 (en) * 2021-04-10 2024-02-14 MEI Pharma, Inc. Voruciclib dosing regimens and methods of treatment including the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140080838A1 (en) * 2012-09-20 2014-03-20 Memorial Sloan-Kettering Cancer Center Methods for Treatment of Lymphomas with Mutations in Cell Cycle Genes

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2219867A1 (en) 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US7271193B2 (en) 2002-07-08 2007-09-18 Nicholas Piramal India, Ltd. Inhibitors of cyclin-dependent kinases and their use
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
ES2382383T3 (es) 2004-06-17 2012-06-07 Infinity Discovery, Inc. Compuestos y procedimientos para inhibir la interacción de proteínas Bcl con componentes de unión
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
PT1888550E (pt) 2005-05-12 2014-09-03 Abbvie Bahamas Ltd Promotores de apoptose
CA2609202C (en) 2005-05-24 2014-12-23 Abbott Laboratories Apoptosis promoters
EP2026805A1 (en) 2006-05-08 2009-02-25 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
AU2006344987B8 (en) 2006-06-21 2013-07-11 Piramal Enterprises Limited Enantiomerically pure flavone derivatives for the treatment of proliferative disorders and processes for their preparation
JP5688288B2 (ja) * 2007-05-15 2015-03-25 ピラマル エンタープライジーズ リミテッド がんの処置のための相乗的な医薬の組合せ
US9259399B2 (en) * 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
KR101633532B1 (ko) 2008-12-19 2016-06-24 제넨테크, 인크. 화합물 및 사용 방법
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
RU2013127655A (ru) 2010-11-19 2014-12-27 Пирамал Энтерпрайзис Лимитед Фармацевтическая комбинация паклитаксела и ингибитора cdk
TW201300105A (zh) 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
CN110305162A (zh) 2013-01-16 2019-10-08 密歇根大学董事会 BCL-2/Bcl-xL抑制剂和使用所述抑制剂的治疗方法
WO2015084892A1 (en) * 2013-12-02 2015-06-11 Cornell University Methods for treating b cell proliferative disorders
EP3476392A1 (en) 2014-02-28 2019-05-01 Merck Sharp & Dohme Corp. Method for treating cancer
WO2015181737A1 (en) 2014-05-28 2015-12-03 Piramal Enterprises Limited Pharmaceutical combination for the treatment of cancer
HRP20211813T1 (hr) * 2014-08-11 2022-03-04 Acerta Pharma B.V. Terapeutske kombinacije inhibitora btk i inhibitora bcl-2
US9637488B2 (en) * 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
KR102545392B1 (ko) * 2016-03-28 2023-06-20 프레시지 바이오싸이언시스, 인크. 암 치료를 위한 제약학적 조합물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140080838A1 (en) * 2012-09-20 2014-03-20 Memorial Sloan-Kettering Cancer Center Methods for Treatment of Lymphomas with Mutations in Cell Cycle Genes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Blood Cancer Journal, Vol. 5, No. e368, pp. 1-8 (2015)*
Cancer Res., Vol. 72, No. 16, pp. 4225-4237 (2012)*
Molecular Cancer, Vol. 11, No. 77, pp. 1-12 (2012)*
Oncogene, Vol. 32, pp. 7108-7122 (2003)*

Also Published As

Publication number Publication date
IL295472A (en) 2022-10-01
US20190275004A1 (en) 2019-09-12
EP3436002A1 (en) 2019-02-06
KR20230093360A (ko) 2023-06-27
JP2019514854A (ja) 2019-06-06
CA3018932C (en) 2021-10-26
KR20230156443A (ko) 2023-11-14
AU2020201247B2 (en) 2021-08-26
IL261824A (en) 2018-10-31
IL261824B2 (en) 2023-02-01
IL295472B2 (en) 2024-10-01
KR20210088016A (ko) 2021-07-13
US20200383948A1 (en) 2020-12-10
MX2018011666A (es) 2019-07-08
KR102494039B1 (ko) 2023-01-30
US20220023261A1 (en) 2022-01-27
US20210283104A1 (en) 2021-09-16
JP7114478B2 (ja) 2022-08-08
MX2022002318A (es) 2022-04-06
IL295472B1 (en) 2024-06-01
US11135198B2 (en) 2021-10-05
JP2022141916A (ja) 2022-09-29
NZ747404A (en) 2020-03-27
CA3018932A1 (en) 2017-10-05
AU2024200194A1 (en) 2024-02-01
ZA201806819B (en) 2022-03-30
EP3436002A4 (en) 2019-12-04
KR20190039878A (ko) 2019-04-16
WO2017172826A1 (en) 2017-10-05
IL261824B (en) 2022-10-01
KR20230021155A (ko) 2023-02-13
AU2021273532A1 (en) 2021-12-16
RU2020121147A (ru) 2021-11-03
IL312398A (en) 2024-06-01
RU2726367C2 (ru) 2020-07-13
CA3103604A1 (en) 2017-10-05
RU2018137687A3 (zh) 2020-04-29
CA3103604C (en) 2023-09-26
KR102599512B1 (ko) 2023-11-07
CN109689047A (zh) 2019-04-26
KR102545392B1 (ko) 2023-06-20
JP2024038227A (ja) 2024-03-19
AU2020201247A1 (en) 2020-03-12
JP7416872B2 (ja) 2024-01-17
AU2017241914A1 (en) 2018-11-08
RU2018137687A (ru) 2020-04-29
AU2021273532B2 (en) 2024-02-01
MX2022011750A (es) 2022-10-18
AU2017241914B2 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
KR102275758B1 (ko) 암 치료를 위한 제약학적 조합물
IL250112B2 (en) Aqueous composition containing paracetamol and ibuprofen
US12121508B2 (en) Pharmaceutical combinations for the treatment of cancer
NZ786342A (en) Pharmaceutical combinations for the treatment of cancer
NZ786330A (en) Pharmaceutical combinations for the treatment of cancer
US12076363B2 (en) Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers
WO2024173833A1 (en) Combination of a cdk inhibitor and a flt3 inhibitor for the treatment of cancer

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
X701 Decision to grant (after re-examination)
A107 Divisional application of patent
GRNT Written decision to grant